Cancer Research Pakistan Project at Chughtai Lab

Understanding the Cancer Research Pakistan Project at Chughtai Lab

The Cancer Research Pakistan Project at Chughtai Lab represents a monumental advancement in the landscape of oncology, molecular diagnostics, and genomic medicine within Pakistan. This specialized initiative is designed to address the unique genetic profile of the Pakistani population concerning various malignancies. By combining cutting-edge diagnostic technologies with clinical research, the project aims to provide comprehensive genetic profiling, early cancer detection, hereditary risk assessment, and personalized treatment pathways for patients across the country. Chughtai Lab, as a premier diagnostic institution in Pakistan, utilizes state-of-the-art molecular biology suites to execute this project, ensuring that patients and clinicians have access to highly accurate, actionable genomic data.

At its core, the Cancer Research Pakistan Project focuses on identifying both germline (inherited) and somatic (acquired) genetic mutations that drive cancer development. Through advanced methodologies such as Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Immunohistochemistry (IHC), the project evaluates critical biomarkers that dictate how a tumor behaves, how aggressive it is, and which targeted therapies will be most effective. This shift from a one-size-fits-all treatment model to precision oncology is vital for improving survival rates and minimizing the side effects of cancer therapies. By analyzing the specific genetic alterations in Pakistani patients, the project also contributes invaluable data to global cancer research, helping to close the gap in representation for South Asian genomes in international oncology databases.

The clinical importance of this project cannot be overstated. Cancer remains one of the leading causes of morbidity and mortality in Pakistan, often diagnosed at advanced stages due to a lack of awareness and limited access to specialized screening. The Cancer Research Pakistan Project at Chughtai Lab addresses these challenges by offering accessible, high-quality genetic screening panels. These panels evaluate genes associated with hereditary breast and ovarian cancer (HBOC) syndromes, Lynch syndrome, and other familial cancer predisposition states. For patients already diagnosed with cancer, the project provides comprehensive tumor profiling to identify actionable mutations, enabling oncologists to prescribe targeted drugs and immunotherapies that specifically attack cancer cells while sparing healthy tissue.

Clinical Procedure: What to Expect

Patient Preparation

Patient preparation for the Cancer Research Pakistan Project at Chughtai Lab depends significantly on the type of sample being analyzed. Because this project encompasses both germline genetic testing and somatic tumor profiling, the preparation guidelines are tailored to the specific specimen required:

• Peripheral Blood Samples (Germline Testing & Liquid Biopsies): For tests evaluating inherited genetic risks or circulating tumor DNA (ctDNA), a simple blood draw is performed. No fasting is generally required for these molecular tests. Patients should remain well-hydrated prior to the blood draw. It is essential to inform the laboratory staff of any recent blood transfusions, as this can temporarily affect the accuracy of germline DNA analysis.
• Tumor Tissue Samples (Somatic Profiling): If the analysis is being performed on a solid tumor, the laboratory will require formalin-fixed paraffin-embedded (FFPE) tissue blocks or unstained slides obtained from a previous biopsy or surgical resection. Patients do not need to undergo any immediate preparation for this, but they must coordinate with their treating surgeon or pathologist to ensure the retrieval and safe transfer of the tissue blocks to Chughtai Lab.
• Medication Review: Patients should provide a complete list of current medications, chemotherapy agents, and immunotherapies to the clinical coordinator, as certain treatments can influence biomarker expression or sample cellularity.

During the Procedure

The procedure varies based on whether the patient is providing a new biological sample or submitting existing tissue:

• Blood Sample Collection: A certified phlebotomist at Chughtai Lab will perform a standard venipuncture, typically drawing blood from a vein in the arm into specialized tubes designed to preserve DNA or RNA stability. The process is quick, taking less than five minutes, and involves minimal discomfort.
• Tissue Sample Submission: For tissue-based testing, the pathology department at Chughtai Lab receives the FFPE blocks. A molecular pathologist reviews the slides to confirm the presence of adequate tumor cellularity (usually a minimum of 20% to 30% tumor content is required for successful NGS analysis).
• Laboratory Processing and Sequencing: Once the sample is verified, genomic DNA or RNA is extracted using automated purification systems. The nucleic acids undergo library preparation, target enrichment, and sequencing on high-throughput Next-Generation Sequencing platforms.
• Bioinformatics and Interpretation: The raw sequencing data is processed through advanced bioinformatics pipelines to identify single nucleotide variants (SNVs), small insertions/deletions (indels), copy number variations (CNVs), and structural rearrangements. A multidisciplinary team of molecular pathologists and geneticists interprets these variants against global clinical databases to generate a comprehensive, personalized report.

When is a Cancer Research Pakistan Project Performed?

Assessment of Hereditary Cancer Predisposition

Physicians recommend genetic screening under the Cancer Research Pakistan Project when a patient exhibits a strong family history of early-onset malignancies. This includes families with multiple cases of breast, ovarian, colorectal, or endometrial cancers, particularly when diagnosed before the age of 50. Identifying germline mutations in genes such as BRCA1, BRCA2, or mismatch repair genes (MLH1, MSH2, MSH6, PMS2) allows for proactive surveillance, prophylactic surgeries, and risk-reduction strategies for both the patient and their close relatives.

Selection of Targeted Oncological Therapies

For patients diagnosed with advanced or metastatic solid tumors, such as non-small cell lung cancer (NSCLC), colorectal cancer, or melanoma, this project is utilized to identify actionable somatic mutations. By detecting specific alterations like EGFR mutations, ALK rearrangements, BRAF V600E mutations, or KRAS variants, the project guides oncologists in selecting highly effective tyrosine kinase inhibitors (TKIs) or other targeted agents, significantly improving progression-free survival compared to standard chemotherapy.

Evaluation for Immunotherapy Eligibility

Immunotherapy has revolutionized cancer treatment, but its efficacy depends on specific tumor biomarkers. The Cancer Research Pakistan Project evaluates critical immunotherapy indicators, including Microsatellite Instability (MSI) status, Mismatch Repair (MMR) deficiency, and Tumor Mutational Burden (TMB). Patients with high MSI or high TMB are excellent candidates for immune checkpoint inhibitors, such as pembrolizumab, which help the patient’s own immune system recognize and destroy cancer cells.

Investigating Cancer of Unknown Primary (CUP)

In clinical cases where metastatic cancer is detected but the primary site of origin cannot be identified through conventional imaging or histopathology, comprehensive genomic profiling is performed. By analyzing the molecular signature and mutational patterns of the metastatic tumor, the project helps pinpoint the likely tissue of origin. This allows clinicians to initiate a more specific and effective site-directed treatment regimen.

Monitoring Disease Burden and Resistance Mechanisms

As cancer cells evolve during treatment, they can develop resistance to targeted therapies. The project utilizes liquid biopsy technology to analyze circulating tumor DNA (ctDNA) from blood samples. This non-invasive method is performed to detect emerging resistance mutations (such as the EGFR T790M or C797S mutations in lung cancer) and to monitor minimal residual disease (MRD), allowing clinicians to adjust treatment strategies before clinical or radiological progression occurs.

What Does a Cancer Research Pakistan Project Detect?

The Cancer Research Pakistan Project at Chughtai Lab utilizes comprehensive molecular panels to detect a wide array of genetic alterations and biomarkers. These findings are critical for diagnostic classification, prognostic assessment, and therapeutic planning. The primary genetic targets and alterations detected include:

• BRCA1 and BRCA2 Germline Mutations: Pathogenic variants indicating a high risk for hereditary breast, ovarian, prostate, and pancreatic cancers.
• EGFR (Epidermal Growth Factor Receptor) Mutations: Somatic mutations in exons 18, 19, 20, and 21, which predict response or resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
• ALK (Anaplastic Lymphoma Kinase) Gene Fusions: Chromosomal rearrangements (such as EML4-ALK) that indicate eligibility for ALK inhibitors.
• ROS1 and RET Proto-oncogene Fusions: Actionable structural variants found in non-small cell lung cancers and thyroid carcinomas.
• KRAS, NRAS, and BRAF Mutations: Critical oncogenic drivers in colorectal cancer and melanoma; their presence helps determine eligibility for anti-EGFR monoclonal antibodies or BRAF/MEK inhibitors.
• PIK3CA Mutations: Alterations associated with resistance to hormone therapy in breast cancer and eligibility for PI3K inhibitors.
• Microsatellite Instability (MSI) / Mismatch Repair (MMR) Status: Detection of MSI-High (MSI-H) or Deficient MMR (dMMR), which are key predictive biomarkers for immunotherapy response across solid tumors.
• Tumor Mutational Burden (TMB): Measurement of the number of somatic mutations per megabase of sequenced DNA, serving as an independent predictor of response to immune checkpoint inhibitors.
• HER2 (ERBB2) Amplification and Mutations: Overexpression or amplification of the HER2 gene, guiding the use of anti-HER2 targeted therapies in breast, gastric, and lung cancers.
• TP53 Gene Alterations: Mutations in the tumor suppressor gene TP53, which are associated with a more aggressive disease course and poor prognosis across multiple cancer types.
• Lynch Syndrome Gene Mutations: Germline variants in MLH1, MSH2, MSH6, and PMS2 associated with hereditary non-polyposis colorectal cancer (HNPCC).
• NTRK1, NTRK2, and NTRK3 Gene Fusions: Rare but highly actionable genomic fusions across various adult and pediatric tumors, targeting with TRK inhibitors.
• HRD (Homologous Recombination Deficiency) Score: Evaluates genomic instability to identify ovarian and breast cancer patients who will benefit from PARP inhibitors.
• JAK2, CALR, and MPL Mutations: Diagnostic markers for myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
• FLT3 and NPM1 Mutations: Prognostic and therapeutic markers in acute myeloid leukemia (AML).
• BCR-ABL1 Fusion Gene: Diagnostic and monitoring marker for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Turnaround Time and Report Access at Chughtai Lab

Due to the highly complex nature of molecular sequencing, bioinformatics analysis, and multidisciplinary clinical interpretation, the turnaround time for the Cancer Research Pakistan Project varies depending on the specific panel ordered. Standard single-gene PCR assays may be completed within 5 to 7 working days, while comprehensive Next-Generation Sequencing (NGS) panels and liquid biopsies typically require 14 to 21 working days to ensure absolute accuracy and thorough clinical annotation.

Chughtai Lab offers a seamless, secure, and highly convenient digital reporting system. Once the molecular pathology board finalizes the genomic report, patients and their referring oncologists receive an automated SMS notification. Reports can be accessed, viewed, and downloaded in secure PDF format via the official Chughtai Lab website or the dedicated Chughtai Lab mobile application. This rapid digital access ensures that critical treatment decisions are not delayed, allowing oncologists to initiate personalized therapy regimens as quickly as possible.

Cancer Research Pakistan Project Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
BRCA1 / BRCA2 Genes	No pathogenic germline variants detected.	Pathogenic or likely pathogenic mutations indicating hereditary breast/ovarian cancer syndrome.
EGFR Mutation Status	Wild-type (no somatic mutations detected in exons 18-21).	Activating mutations (e.g., Exon 19 deletions, L858R) or resistance mutations (T790M, C797S).
ALK Gene Rearrangement	Negative for ALK gene fusions.	Positive for ALK translocation (e.g., EML4-ALK fusion), indicating eligibility for targeted TKIs.
Microsatellite Instability (MSI)	Microsatellite Stable (MSS).	Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR).
Tumor Mutational Burden (TMB)	Low TMB (< 10 mutations/megabase).	High TMB (≥ 10 mutations/megabase), suggesting high likelihood of immunotherapy response.
KRAS / NRAS Codons	Wild-type (no mutations detected in codons 12, 13, 59, 61, 117, 146).	Somatic mutations predicting resistance to anti-EGFR monoclonal antibody therapies in colorectal cancer.
BRAF Gene (Codon 600)	Wild-type (no V600 mutations).	BRAF V600E or V600K mutation, indicating eligibility for combined BRAF/MEK inhibitor therapy.
PD-L1 Expression (IHC)	No expression or low expression (TPS < 1%).	High PD-L1 expression (TPS ≥ 50%), indicating first-line monotherapy with pembrolizumab.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Cancer Research Pakistan Project?

• College of American Pathologists (CAP) Aligned Standards: Chughtai Lab maintains rigorous quality control protocols aligned with international standards to ensure the highest accuracy in genomic testing.
• Advanced Next-Generation Sequencing (NGS) Infrastructure: Equipped with state-of-the-art sequencing platforms capable of analyzing complex multi-gene panels.
• Expert Molecular Pathology Team: Reports are analyzed and signed off by highly qualified molecular pathologists, geneticists, and bioinformaticians.
• Comprehensive Diagnostic Portfolio: Offers a wide range of oncological tests, from immunohistochemistry to advanced liquid biopsies and germline panels.
• Nationwide Sample Collection Network: Convenient sample collection centers located in major cities across Pakistan, including Lahore, Karachi, Islamabad, and Peshawar.
• Dedicated Genetic Counseling Support: Provides guidance to patients and families navigating hereditary cancer risks and genetic test results.
• Secure Digital Portal and Mobile App: Fast and secure online access to diagnostic reports for both patients and healthcare providers.
• Commitment to Local Genomic Research: Active participation in documenting the genetic landscape of cancer in Pakistan, contributing to better healthcare outcomes nationwide.